

#### This is an Education Platform

We provide Free PDF Notes and Videos Classes for Pharmacy Students

Web Site <a href="http://www.fdspharmacy.in/">http://www.fdspharmacy.in/</a>

You tube <a href="https://www.youtube.com/channel/UC77iEsiuZolU4pB8WAJIR5Q">https://www.youtube.com/channel/UC77iEsiuZolU4pB8WAJIR5Q</a>

What app <a href="https://chat.whatsapp.com/IzSgXtFEvhS4LN5xhUgq5z">https://chat.whatsapp.com/IzSgXtFEvhS4LN5xhUgq5z</a>

Telegram <a href="https://t.me/+cvxmi7xSloA4MjVl">https://t.me/+cvxmi7xSloA4MjVl</a>

Face book <u>https://www.facebook.com/Fdspharmacy-105764311994440/</u>

E-mail fdspharmacyinfo@gmail.com



#### Diploma in Pharmacy 2<sup>nd</sup> Year Hospital & Clinical Pharmacy Experiment

# To fill up IPC's ADR reporting form and perform causality assessments using various scales.

#### Aim:

To fill up IPC's ADR reporting form and perform causality assessments using various scales.

### **Reference :**

<sup>6</sup> Dr. Gupta G.D. , Dr. Sharma Shailesh, Dr. Sharma Anshu, "Practical Manual of Hospital & Clinical Pharmacy" Published by Nirali Prakashan, Page no 13 - 18

# **Theory**:

# Suspected Adverse Drug Reaction Reporting Form

For documenting adverse drug reactions, the NCC has designed a "Suspected Adverse Drug Reaction Reporting Form". There are several forms for recording adverse reactions to blood transfusions, blood-related products, and Adverse Event Following Immunization (AEFD)

ICSR is a report that includes details about a suspected Adverse Drug Reaction (ADR) associated with the administration of one or more medications to a specific patient. The points listed below should be completed on an ADR form:

#### A) Patient Information

1) **Patient Initials**: The initials of a patient should be written instead of full name. For example, Madhu Gupta should be written as MG.



- 2) Age at Time of Event or Date of Birth: Either the date of birth or age of the patient should be written when the event or reaction has occurred.
- 3) **Sex:** The gender of the patient should be mentioned.
- 4) Weight: The weight of the patient should be mentioned.

#### **B)** Suspected Adverse Reaction

- 5) **Date of Reaction Started:** The date on which the reaction initially appeared should be mentioned
- 6) **Date of Recovery:** If the reaction recovered, the patient's recovery date from the reaction should be reported.
- 7) Describe Reaction: Description of the reaction, including its type. location, etc. should be provided. For example, an erythematous maculopapular rash appeared on the patient's upper and lower limbs.

#### C) Suspected Medications

- 8) The reporter should provide information about any suspected medications, including the drug name (brand or generic name), manufacturer, batch number or lot number, expiry date, dose used, route of administration, frequency, dates of therapy started and ended, and indication.
- 9) **Dechallenge Details:** The status on dechallenge should be mentioned as:
  - i) 'Yes': If the reaction subsides after dechallenge
  - ii) 'No': If the reaction does not subsides after der hallenge
  - iii) 'Unknown': If effect of dechallenge is not known.
  - iv) "Not Applicable' or 'NA': When dechallenge is unnecessary, as it is when it comes to things like vaccines, anaesthesia, the delivery of only one dose, patient death, or the end of therapy before a reaction or occurrence.
  - v) '**Reduced Dose':** If dose at which the reaction occurred is reduced?

Note: Reduced dose and date should also be mentioned

- 10) **Re-challenge Details:** The status on re-challenge should be mentioned as
  - i) **'Yes':** If reaction reappeared after re-challenge.
  - ii) 'No': If reaction does not reappear after re-challenge.
  - iii) 'Unknown': If effect of re-challenge is not confirmed.
  - iv) Not Applicable' or 'NA': If re-challenge is not applicable as in case of anaphylaxis reaction.
  - v) **Re-Introduced Dose':** Mention the dose and date of rechallenge The dose and date or re-challenge should be mentioned.
  - 11) **Concomitant Drugs:** The details of all concurrent drugs including self- medication, OTC medication, herbal remedies with therapy dates should be recorded.
  - 12) **Relevant Tests/Laboratory Data:** All the laboratory data (if available) that are related to the reaction should be mentioned.
  - 13) **Other Relevant History:** The related history of patient including pre- existing medical condition (such as, allergies, pregnancy, smoking. alcohol use, hepatic/renal dysfunction) and concurrent condition should be noted.
  - 14) **Seriousness of the Reaction:** The relevant cause for seriousness should be marked if any reaction is serious in nature:
    - i) 'Death': If a negative incident caused the patient's death Note: The cause and date of the death should be mentioned in the seriousness of the reaction.
    - ii) **'Life-Threatening':** If the patient was at serious risk of dying when the adverse event occurred.
    - iii) 'Hospitalisation/Prolonged': If the adverse event extended the patient's hospital stay or caused hospitalisation.



- iv) 'Disability': If adverse event caused a person's ability to carry out regular living functions to be significantly disrupted.
- v) **'Congenital Anomaly':** If taking drugs during or before would have harmed the unborn child. pregnancy
- vi) 'Required Intervention to Prevent Permanent Impairment/Damage': If a body function or structure needed to be protected against permanent impairment through medical or surgical intervention
- vii) 'Other': When the conditions do not fulfil the criteria above, yet it could still be dangerous for the patient and require a surgical or medical procedure to avoid one of the above conditions.
  For example, severe blood dyscrasias (blood disorders), non-hospitalised seizures or convulsions, the emergence of drug dependence, or drug addiction.
- 15) **Outcomes:** The outcome of the event should be marked:
  - i) 'Fatal': If the patient dies
  - ii) '**Continuing':** If the patient is continuing to experience the reaction.
  - iii) '**Recovering**': If the patient is recovering from the reaction.
  - iv) '**Recovered':** If the patient has completely recovered from the reaction (mention the date of recovery).
  - v) '**Unknown**': If the outcome is not known.

#### D) Reporter

- 16) **Name and Professional Address**: The patient name and address should be mentioned on the form by the reporter. The identity of the reporter should be maintained
- 17) **Causality Assessment:** If trained, the reporter should determine the causality and support the determination.



18) **Date of Report:** The date on which he/she reported the adverse event should be mentioned.

All the required information should be collected to fill in suspected ADR reporting form. All the Essentially Required Items (ERI) should be filled for quality ICSR if complete information is not available. It should be ensured that the form must include all the mandatory fields if ERI is not available.

Mandatory Fields	Es <mark>sentially Require</mark> d Items
Initials of the patient, age at response	Patient initials, age at onset of reaction.
onset, reaction term(s), and date of	gend <mark>er, reaction term(s), dat</mark> e of onset
reaction onset, suspected medication,	of reaction, suspected medication(s),
and reporter s details should be filled.	dose. d <mark>ate of therapy sta</mark> rted,
	indication of use, seriousness,
	outcome, dechallenge and rechallenge
	details, reporter's information and date
	of report should be filled.

Note: For a valid case report mandatory fields are the minimum requirement

earn and Educate



S.No. 8. Name (Brand/Generic) Manufacturer No. (if known) (Brand/Generic) /Lot No. (if known)	C. Suspected Medication(S)			7. Describe reaction or problem	6. Date of recovery (dd/mm/yyyy)	5, Date of reaction started (dd/mm/yyyy)	B. Suspected Adverse Reaction	ate of Birth 4. Weight	A. Patient Information	Report Type  Initial  Follow up	Sector-23, Raj Nagar, Ghaziabad-201002	(National Coordination Centre-Pharmacovigilance Programme of India)	For VOLUNTARY Reporting of Adverse Drug Reaction Reporting
used Route Frequency Therapy dates Indication used (OD, BD Date Date etc.) started stopped		□ Recovered □ Recovering □ Not □ Fatal □ Recovered with sequeted Unk	14. Seriousness of the reaction: No □ if Yes □ (please tick anyone)         □ Death (dd/mm/yyyy)       □ Congenital-anomaly         □ Life threatening       □ Required intervention to         □ Hospitalisation/Prolonged       Prevent permanent         □ Disability       □ Other (specify)		o	Smoking, alcohol use, henatic/renal dysfunction atc.)	12 Belance P W P A A	er  kgs kgs	12 Believe No.:	Worldwide II-:	AMC Report No.:	ia) For AMC/NCC Use Only	For VOLUNTARY Reporting of Adverse Drug Reactions hv Healthcare Drofessional
Causality Assessments	The second second	Not recovered Unknown	ick anyone) i to			ce, pregnancy,	and the set						

n (please tick)  n (ple	No     9. Action Taken (please tick).     Io. Reaction reappeared after reintroduction (please tick).       r C     Unknown     Yes     No     Effect     Dose increased       r C     withdrawn     Dose increased     Dose increased     changed     applicable     Unknown     Yes     No       r C     withdrawn     Nos     Dose increased     Dose increased     Dose (if nose)     Dose (if nose)       r C     withdrawn     Yes     No     Effect     Dose (if nose)       r Drug     No     No     Yes     No     Effect     Dose (if nose)       r Drug     No     None (Brand/Generic)     Dose used     Route used     Route used     Proc.)     Date started     Date stoped       No     Name (Brand/Generic)     Dose used     Route used     Route used     Route used     No       No     Name (Brand/Generic)     Dose used     Route used     Route used     Dose (if Name)       No     Name (Brand/Generic)     Dose used     Route used     Route used     Route used       No     Name (Brand/Generic)     Dose used     Route used     Dose used     Route used       No     Name (Brand/Generic)     Dose used     Route used     Route used     Route used       No     No	No       9. Action Taken (please tick).       10. Reaction reappeared after reintroduction (please tick).         rC       Drug       Dose increased       Dose not       Not       Ves       No         rC       withdrawn       Dose increased       changed       applicable       Unknown       Yes       No       Unknown       reintroduction (please tick).         rC       withdrawn       Dose increased       changed       applicable       Unknown       Yes       No       Unknown       Pose (if         reintroduction       Mone       Brand/Generic)       Dose used       Roure used       Roure used       Frequency (OD).       Therapy dates (Exclude those used to treat reaction).         Konconnitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction).       Indication         Konconnitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction).       Indication         Konconnitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction).       Indication         Konconnitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction).       Indication         Mone       Name (Brand/Generic)       Dose used       Rout with Self       Indication	No 9. Action Taken (please tick) Drug Dose increased withdrawn Dose increased Concomitant medical product including								
In (please tick)     IO. Reaction reappeared after reintroduction (please tick)       Dose increased     Dose not     Not     Unknown     Yes     No     Effect       Dose increased     changed     applicable     Unknown     Yes     No     Effect       In product increased     changed     applicable     Unknown     Yes     No     Effect       In product increased     changed     applicable     Unknown     Yes     No     Effect       In product increased     changed     applicable     Unknown     Yes     No     Effect       In product increased     changed     applicable     Unknown     Yes     No     Internovn       In product increased     pose used     Route used     Frequency (OD,     Therapy dates     Internov       (Generic)     Dose used     Route used     BD, etc.)     Date started     Date stopped       In transitional dates     Dose used     Route used     Internov (OD,     Therapy dates       In transitional     Dose used     Route used     BD, etc.)     Date started     Date stopped       In transitional     Dose used     Route used     Internov (OD,     Therapy dates     Internov       In transitional     Dose used     Route used     Internov (OD, <td< th=""><th>No     9. Action Taken (please tick).     10. Reaction reappeared after reintroduction (please tick).       rC     Viuhdravan     Dose     Dose     Dose     Dose     Dose (rf       rC     viuhdravan     Dose increased     Dose     Dose     Dose (rf     Dose (rf       rC     viuhdravan     Dose increased     Dose used     changed     applicable     No     Effect     Dose (rf       rC     viuhdravan     Ves     No     Fectured (rf     Action Taken)     Effect     Dose (rf       rC     Viuhdravan     Dose (rf     applicable     Action terapeared after reintroduction (please tick)       rC     Viuhdravan     Dose (rf     Action terapeared     Dose (rf     Dose (rf       Concomitant medical product including self-medication and herbal ternedies with therapy dates (Exclude those used to teat reaction)     Indication       No     Name (Brand/Generic)     Dose used     Route used     Fequency (OD, Rest (rf     Therapy dates       ditional Information:     Actional function:     BD, etc.)     Date started     Date stopped     Indication       ditional Information:     Information:     Information:     Information:     Information:     Information:</th><th>No       9. Action Taken (please tick)       10. Reaction reappeared after reintroduction (please tick)         rC       Vinhdrawn       Dose increased       Dose not       No       Unknown       Yes       No       Dose (if         rC       vinhdrawn       Dose increased       coloced       changed       applicable       Inknown       Yes       No       Effect       Dose (if         rC       vinhdrawn       Dose increased       coloced       changed       applicable       Inknown       Yes       No       Effect       Dose (if         rC       Vinhdrawn       Dose increased       Rouce clanged       applicable       Inknown       Yes       No       Inknown       Dose (if       Do</th><th>No 9. Action Taken (please tick) r C Drug Dose increased withdrawn Dose increased Concomitant medical product including</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></td<>	No     9. Action Taken (please tick).     10. Reaction reappeared after reintroduction (please tick).       rC     Viuhdravan     Dose     Dose     Dose     Dose     Dose (rf       rC     viuhdravan     Dose increased     Dose     Dose     Dose (rf     Dose (rf       rC     viuhdravan     Dose increased     Dose used     changed     applicable     No     Effect     Dose (rf       rC     viuhdravan     Ves     No     Fectured (rf     Action Taken)     Effect     Dose (rf       rC     Viuhdravan     Dose (rf     applicable     Action terapeared after reintroduction (please tick)       rC     Viuhdravan     Dose (rf     Action terapeared     Dose (rf     Dose (rf       Concomitant medical product including self-medication and herbal ternedies with therapy dates (Exclude those used to teat reaction)     Indication       No     Name (Brand/Generic)     Dose used     Route used     Fequency (OD, Rest (rf     Therapy dates       ditional Information:     Actional function:     BD, etc.)     Date started     Date stopped     Indication       ditional Information:     Information:     Information:     Information:     Information:     Information:	No       9. Action Taken (please tick)       10. Reaction reappeared after reintroduction (please tick)         rC       Vinhdrawn       Dose increased       Dose not       No       Unknown       Yes       No       Dose (if         rC       vinhdrawn       Dose increased       coloced       changed       applicable       Inknown       Yes       No       Effect       Dose (if         rC       vinhdrawn       Dose increased       coloced       changed       applicable       Inknown       Yes       No       Effect       Dose (if         rC       Vinhdrawn       Dose increased       Rouce clanged       applicable       Inknown       Yes       No       Inknown       Dose (if       Do	No 9. Action Taken (please tick) r C Drug Dose increased withdrawn Dose increased Concomitant medical product including								
In (please tick) In (please tick) In (please tick) Dose increased Teduced Toologe the point of t	No     9. Action Taken (please tick)     10. Reaction reappeared after reintroduction (please tick)       r C     withdrawn     Dose increased     reduced     changed     applicable     Unknown     Yes     No     Effect     Dose (if       r C     withdrawn     Dose increased     reduced     changed     applicable     Unknown     Yes     No     Effect     Dose (if       r C     withdrawn     Yes     No     Effect     Dose (if     Dose (if       r Concomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction)     Indication       Concomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction)     Indication       Konomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction)     Indication       Konomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction)     Indication       Konomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction)     Indication       Konomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction)     Indication       Konomitant medical product including the self-medication and herhal remedies with therapy dates     Indication	No       Action Taken (please tick)       10. Reaction reuppeared after reintroduction (please tick)         rC       Ubrug       Dose increased       Dose not       Not       Effect       Dose (if         rC       withdrawn       Dose increased       changed       applicable       Unknown       Yes       No       Effect       Dose (if         rC       withdrawn       Dose increased       changed       applicable       Unknown       Yes       No       Effect       Dose (if         No       Name (Brand/Genetric)       Dose used       Route used       Frequency (OD.       Therapy dates       Indication         No       Name (Brand/Genetric)       Dose used       Route used       Frequency (OD.       Therapy dates       Indication         Mitomal Information:	No 9. Action Taken (please tick) Drug Dose increased r C withdrawn 0 e increased								
applicable     I0. Reaction reappeared after reintroduction       sed     Dose not     Not     Unknown     Yes     No     Effect       reduced     changed     applicable     Innknown     Yes     No     Effect       uding self-medication and herbal remedies with therapy dates (Exclude those used     Frequency (OD,     Therapy dates (Exclude those used to treat reaction)       Dose used     Route used     BD, etc.)     Date started     Date stopped       Pin:     E-mail       Fiel. No. (with STD code)     Tel. No. (with STD code)	No       9. Action Taken (please tick)       10. Reaction reappeared after reintroduction (please tick)         rC       brug       Dose increased       Dose       Dose not       Not       Unknown       Yes       No       Effect       Dose (if         reduced       changed       changed       applicable       Unknown       Yes       No       Effect       Dose (if         No       methor       reduced       changed       changed       changed       changed       applicable       bose (if       Dose (if       Do	In (please tick) Dose increased after reintroduction ( please tick) Dose increased reduced changed applicable Not Ves No Effect reduced changed applicable Not Ves No Effect reduced changed applicable Dose used to treat reaction. If product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) (Generic) Dose used Route used Frequency (OD, Therapy dates (Exclude those used to treat reaction)  (Generic) Dose used Route used Frequency (OD, Date started Date stopped Date stopped	No 9. Action Taken (please tick) Drug Dose increased withdrawn Dose increased								
Dose increased     Dose increased     Dose increased     Dose unknown     Yes     No     Effect       reduced     changed     applicable     http://withinteraprocesconsection     http://withinteraprocesconsection     http://withinteraprocesconsection       If product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction)     ftequency (OD, Therapy dates (Exclude those used to treat reaction)       (Generic)     Dose used     Route used     BD, etc.)     Date started     Date stopped       // for the interaption     interaprocesconsection     interaprocesconsection     interaprocesconsection	Clication     Dose increased     Dose not     Not     Unknown     Yes     No     Effect     Dose (if       Nuthdrawn     reduced     changed     applicable     applicable     how     Yes     how     reintroduced       No     Name (Brand/Generic)     Dose used     Route used     Route used     Frequency (D).     Therapy dates     Indication       No     Name (Brand/Generic)     Dose used     Route used     Route used     BD, etc.)     Date started     Date stopped     Indication       No     Name (Brand/Generic)     Dose used     Route used     Route used     Frequency (OD,     Therapy dates     Indication       No     Name (Brand/Generic)     Dose used     Route used     Route used     Frequency (OD,     Therapy dates     Indication       No     Name (Brand/Generic)     Dose used     Route used     Route used     Frequency (OD,     Therapy dates     Indication       No     Name (Brand/Generic)     Dose used     Route used     Indication     Date started     Date stopped     Indication       Alional Information:	Cling         Dose increased         Entitroduced)	r C Drug Dose increased withdrawn Dose increased Concomitant medical product including					10. Reaction	n reappeare	d after reintroduc	tion (please tick)
Interview     Interview     Interview     Interview     Interview     Interview	Image: Note of the set of t	Interpret in the interpret of the interpret i	Concomitant medical product including	Dose reduced	Dose not changed	Not applicable	Unknown	Yes	No	Effect unknown	Dose (if reintroduced)
Il product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) /Generic) Dose used Route used Frequency (OD, Therapy dates BD, etc.) Date started Date stopped Date started Date stopped D. Reporter Details I. 6. Name and Professional Address: Detail Tel. No. (with STD code) Signature:	Name (Brand/Generic)     Dose used     Route used     Frequency (OD, Name (Brand/Generic)     Indication       Vo     Name (Brand/Generic)     Dose used     Route used     Frequency (OD, BD, etc.)     Therapy dates     Indication       Vo     Name (Brand/Generic)     Dose used     Route used     BD, etc.)     Date started     Date stopped       Indication     BD, etc.)     Date started     Date stopped     Indication       Information:	Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction)       Indication         Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction)       Indication         Vo       Name (Brand/Generic)       Dose used       Route used       Frequency (OD, Therapy dates       Indication         Model       BD, etc.)       Date started       Date stopped       Indication         Itional Information:	Concomitant medical product including						·		
International product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction)       Generic     Dose used     Route used     Frequency (OD, BD, etc.)       Generic     Dose used     Route used     BD, etc.)       Date started     Date started     Date stopped       International     International Address:     International Address:	Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction)       Vo     Name (Brand/Generic)     Dose used     Route used     Frequency (OD, Route used     Frequency (OD, BD, etc.)     Indication       Vo     Name (Brand/Generic)     Dose used     Route used     Route used     BD, etc.)     Date started     Indication       Indication     BD, etc.)     Date started     Date stopped     Indication       Information:     Information:     Information:     Information:     Information:       Information:     Information:     Information:     Information:     Information:	Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction)       Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction)       No     Name (Brand/Generic)     Dose used     Route used     Frequency (OD, BD, etc.)       No     Name (Brand/Generic)     Dose used     Route used     Frequency (OD, BD, etc.)     Therapy dates       Indication     BD, etc.)     Date started     Date stopped       Indication:     Date started     Date started     Date stopped       Indication:     Date started     Date started     Date stopped       Indication:     Date started     Date started     Date started       Indication:     Date started     Date started     Date stopped       Indication:     Date started     Date started     Date started       Indication:     Date of t	Concomitant medical product including								
If product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) Generic) Dose used Route used Frequency (OD, Therapy dates BD, etc.) Date started Date stopped Date started Date stopped Date started Date stopped 16. Name and Professional Address: Tel. No. (with STD code) Signature: Occupation:Signature:	Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) Vo Name (Brand/Generic) Dose used Route used Frequency (OD, Therapy dates (Exclude those used to treat reaction) Nome (Brand/Generic) Dose used Route used Route used ED, etc.) Date started Date stopped Indication Indicat	Concomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction)       Indication         Vo       Name (Brand/Generic)       Dose used       Route used       Frequency (OD, Route used       Frequency (OD, Route used       Indication         Indication       BD, etc.)       Date started       Date stopped       Indication         Information:       Information:       Indication       Indication       Indication         Information:       Information:       Information:       Information:       Information:         Information:       Information:       Information:       Information:       Information:       Information:         Information:       Information:       Information:       Information:       Information:       Information:         Information:       Information:       Information:       Information:       Infor	Concomitant medical product including								
If product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) A Generic) Dose used Route used Frequency (OD, Therapy dates BD, etc.) Date started Date stopped Date stored Date stopped Date started Date stopped Date stored Date stopped Date stored Date	Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction)         No       Name (Brand/Generic)       Dose used       Route used       Frequency (OD, BD, etc.)       Therapy dates       Indication         No       Name (Brand/Generic)       Dose used       Route used       Frequency (OD, BD, etc.)       Therapy dates       Indication         Information:       D. Reporter Otal       Date started       Date stopped       Date stopped       Indication         ditional Information:       I. Reporter Details       I. Reporter Details       I. No. (with STD code)       Indication         fittional Information:       I. No. (with STD code)       I. No. (with STD code)       Indication	Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction)         Vo       Name (Brand/Generic)       Dose used       Route used       Frequency (OD,       Therapy dates       Indication         vio       Name (Brand/Generic)       Dose used       Route used       Frequency (OD,       Therapy dates       Indication         diftional Information:	Concomitant medical product including								
/Generic)     Dose used     Route used     Frequency (OD, BD, etc.)     Therapy dates       BD, etc.)     Date started     Date stopped       IG     IG     None and Professional Address:       Pin:     F-mail       Tel. No. (with STD code)       Occupation:     Signature:	Name (Brand/Generic)     Dose used     Requency (OD, BD, etc.)     Therapy dates     Indication       Initional Information:     BD, etc.)     Date started     Date stopped     Indication       Information:     Information:     Information:     Information:     Information:     Information:       Information:     Information:     Information:     Information:     Information:     Information:	Vol       Name (Brand/Generic)       Dose used       Route used       Frequency (OD, BD, etc.)       Therapy dates       Indication         iftional       intervalue       intervalue       intervalue       intervalue       indication         iftional       intervalue       intervalue       intervalue       indication       indication         iftional       information:       intervalue       intervalue       indication       indication         iftional       information:       intervalue       intervalue       intervalue       indication         iftional       information:       intervalue       intervalue       indication       indication         iftional       information:       intervalue       intervalue       intervalue       indication         iftional       information:       intervalue       intervalue       intervalue       indication         iftional       information:       intervalue       intervalue       intervalue       indication         iftional       intervalue       intervalue       intervalue       intervalue       intervalue         iftional       intervalue       intervalue       intervalue       intervalue       intervalue         iftional       intore       interva		r self-medica	tion and herba	I remedies with	th therapy da	ates (Exclude t	hose used t	treat reaction)	
Date started	Date started     Date started     Date stopped       Information:     D. Reporter Details	Date started     Date started     Date stopped       fitional Information:     D. Reporter Details     Date stopped       fitional Information:     D. Reporter Details     D. Reporter Details	Name (Brand/Generic)	ose used	Route used	Frequency BD, etc	(OD,	Ther	apy dates		Indication
D. Reporter Details       16. Name and Professional Address:       Fin:       E-mail       Occupation:	litional Information:  Informa	litional Information: If it is not expected to the fullest extent. Programme staff is not expected to and will not d If it is not expected to the fullest extent. Programme staff is not expected to and will not d reporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manuf						Date started	Date	stopped	- m -
D. Reporter Details       D. Reporter Details       16. Name and Professional Address:       Pin:       Fin:       Tel. No. (with STD code)       Occupation:	litional Information:       D. Reporter Details       D. Reporter Details       16. Name and Professional Address:       17. No. (with STD code)       Signature:       17. Date of this report (dd/mm/yyy):	fitional Information:  Information: Information: Informati					No. of Contraction of				
D. Reporter Details       16. Name and Professional Address:       Pin:       F-mail       Tel. No. (with STD code)       Occupation:	Iftional Information:       D. Reporter Details       16. Name and Professional Address:       17. Date of this report (dd/mm/yyyy):	If it on a ln formation:       D. Reporter Details       If and Professional Address:       If and Professional Address:       If a number of this report (dd/mm/yyyy):       If a number of this report (dd/mm/yyyy):       If a number of a request from the public. Submission of a report does not constitute an admission that medical personnel or manuf					A VALLE	5 6	A. I.		
16. Name and Professional Address:         Pin:       E-mail         Tel. No. (with STD code)         Occupation:	16. Name and Professional Address:         16. Name and Professional Address:         Pin:       E-mail         Pin:       E-mail         Pin:       Decempation:         Occupation:       Signature:         17. Date of this report (dd/mm/yyyy):	I6. Name and Professional Address:         16. Name and Professional Address:         Pin:       E-mail         Pin:       E-mail         Tel. No. (with STD code)       Signature:         Occupation:       Signature:         17. Date of this report (dd/mm/yyyy):         I7. Date of this report (dd/mm/yyyy):         reporter's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not d         eporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manuf	ditional Information:	- 7 -		D.	Reporter D	etails		Sec. 1	
lail	Pin:       E-mail         Tel. No. (with STD code)	Fin:       E-mail         Tel. No. (with STD code)				16.	Name and	Professional A	ddress:		
	Decupation:     Signature:       0.0cupation:     0.0cupation:       17. Date of this report (dd/mm/yyyy):	Internation:       Signature:         Internation:       Sidentity in res				-E	1: No (with	E-mail			
and	17. Date of this report (dd/mm/yyyy):	<b>Ifdentiality:</b> The patient's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not d eporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manuf				0.00	cupation:		Si	gnature:	
17. Date of this report (dominy)	rest and will not a start artent Programme staff is not expected to and will not o	fidentiality: The patient's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not d eporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manuf				17.	. Date of thi	s report (dd/m	m/yyyy):		



#### **Case Study**

On 12.01.2016, 65-year-old Madan Lal was taken to the hospital after experiencing upper stomach pain and nausea for the last 5 days. A yellowish discoloration in the nail bed, conjunctiva, and hand was discovered during a physical examination. His weight was 72 kg.

He experienced a few psychotic attacks, for which he has been receiving chlorpromazine medication for the last four weeks. When questioned, he told that he was taking 4 Tab. of Largactil (Chlorpromazine) 100 mg pills before bed. Before being admitted to the hospital, he was also taking Tab. Diclofenac 50 mg twice day for three days due to gastrointestinal pain. On the day of admission, he was examined for the following laboratory parameters:

```
Alkaline Phosphatase = 180 U/L (Normal Range: 25-100 U/L)
ALT=205 U/L (Normal Range: 10-40 Units/L)
Total Bilirubin = 5.0 mg/dL (Normal Range: 0.8-1.2 mg/dL)
```

Treatment with Diclofenac and chlorpromazine was stopped on admission. The level of pain decreased after stopping the medication for 7 days. Additionally, he was re-examined for above parameters as indicated above: Alkaline Phosphatase = 110 IU/L ALT=98 Units/L Total Bilirubin = 1.8 mg/dL

Note: Tab Chlorpromazine Brand Manufacturer: Wedley labs 1 Batch number: LGL088

Name:

LARGACTIL,

Expiry date: Dec 2018



#### A. Patient Information

- Patient Initials ML 1
- Age at the time of Event or Date of Birth-65 years 2
- Sex 3 Male

Female

Other

Weight (kg)-72 kg 4

#### **B. Suspected Adverse Reaction**

- Date of Reaction started (dd/mm/yyyy): 07.01.2016 5
- 6 Date of recovery (dd/mm/yyyy):
- Describe reaction or problem
- Patient was taking Chlorpromazine since 12.12.2015 He developed pain in abdomen 7 And nausea since 07.01 2016. Examination revealed yellowish discoloration of conjunctiva, palm and nails Patient was admitted on 12.01.2016 and investigated. Live function tests indicated raised serum bilirubin, ALT and alkaline phosphatase Drugs were discontinued. On discontinuation of drug, reaction subsided in one week

#### **C. Suspected Medication**

- Name (Brand and/or Generic): Tab. Chlorpromazine (Largactil)
- 8 Manufacturer (if known): Wedley labs Batch No/Lot No: LGL0881 Exp. Date (if known): Dec 2018 Dose used: 400 mg Route used: Oral Frequency (OD, BD, etc): OD Therapy dates Date Started 12.12.2015 Date Stopped 12.01.2016 **Indication:** Psychosis
  - **Causality Assessment: Probable**



Yes	No	ed after	e reduced reintroduct Effect unkn	Dose not changed ion (please to own	Not applicable tick) Dose (if reints	Unknown roduced)
eaction r Yes	No			A REPORT OF THE	ick) Dose (if reintr	roduced)
Yes	No			A REPORT OF THE	ick) Dose (if reinti	roduced)
Yes	No			A REPORT OF THE	ick) Dose (if reinti	roduced)
Yes	No			A REPORT OF THE	tick) Dose (if reintr	roduced)
Yes	No			A REPORT OF THE	bick) Dose (if reinti	roduced)
Yes	No			A REPORT OF THE	Dose (if reint	roduced)
	and share					1.4
	1100	dan gi	and the first			
			1 A. 1 . 1			
	1.1.8					
		1 - 1	1-1 (314)-	ETCL - APPEND	Harth Cold Hart	
	lf-medicat	ion and he	erbal remedie	s with therapy	6 martine	
Name	Dose	Route	Frequenc			Indication
Contraction of the State of the	used	Used	and the second sec	Date	COLOR DATE:	
			1			Pain in
Diclofena	50 mg	Oral	BD	6	6	abdomen
č						
						1
						-
2.01.2016 Alkaline P J/L ALT = 205 Fotal Bilir Relevant I	6 Phosphata 5 U/L ubin = 5.0 <b>medical/r</b>	se = 180 ) mg/dL <b>nedicati</b>	19.01.20 Alkaline ALT = 9 Total Bi on history	916 9 Phosphatas 98 U/L 1 lirubin = 1.8	mg/dL	
etc.)			ncy, smokir	ig, alcohol u	se, hepatic/rei	nal dysfunctio
No Death (dd/	If /mm/yyyy	yes		(Please tick	anyone)	
Hospitalisa Disability Congenita Required i	ation (init l anomaly nterventio	,		nent impairm	ient/damage	
	Name Brand/G eneric) Tab. Diclofena c Relevant f 2.01.2010 Alkaline F J/L ALT = 20: Total Bilir Relevant f e.g. allerg otc.) Seriousness No Death (dd/ Life threat Hospitaliss Disability Congenita Required i	Name       Dose         Brand/G       used         Tab.       50 mg         Diclofena       c         C       So mg         Relevant tests/labo       2.01.2016         Alkaline Phosphata       J/L         ALT = 205 U/L       Cotal Bilirubin = 5.0         Calevant medical/r       e.g. allergies, race, stc.)         Seriousness of the r       If         Death (dd/mm/yyyy)       Life threatening         Hospitalisation (init)       Disability         Yongenital anomaly       Congenital anomaly	Name Brand/G eneric)Dose usedRoute UsedTab. Diclofena c50 mgOralTab. Diclofena c50 mgOralRelevant tests/laboratory G 2.01.2016Alkaline Phosphatase = 180 J/LALT = 205 U/L Cotal Bilirubin = 5.0 mg/dL Relevant medical/medicati e.g. allergies, race, pregnatic.)Seriousness of the reaction: NoIf yes Death (dd/mm/yyyy) Life threatening Hospitalisation (initial or pro Disability Congenital anomaly Required intervention to pre	Brand/GusedUsedy (OD, BD, etc.)Tab.50 mgOralBDDiclofenacIIcIIIRelevant tests/laboratory data with da19.01.20Alkaline Phosphatase = 180AlkalineJ/LALT = 9ALT = 205 U/LTotal BiTotal Bilirubin = 5.0 mg/dLRelevant medical/medication historye.g. allergies, race, pregnancy, smokinitoutIf yesIDeath (dd/mm/yyyy)Life threateningHospitalisation (initial or prolonged)DisabilityCongenital anomalyRequired intervention to prevent permar	Name Brand/GDose usedRoute UsedFrequenc y (OD, BD, etc.)Therap Date StartedTab. Diclofena c50 mgOralBD09.01.201 6CImage: StartedImage: Started6CImage: StartedImage: Started1mage: StartedCImage: StartedImage: Started1mage: Started </td <td>Name Brand/G eneric)Dose usedRoute UsedFrequenc y (OD, BD, etc.)Therapy dates DateTab. Diclofena c50 mgOralBD09.01.20112.01.201Tab. c50 mgOralBD09.01.20112.01.201Caab666Caab10.01.20166Caaba10.01.20166Caaba10.01.20166Caaba10.01.201610.01.2016Alkaline Phosphatase = 180Alkaline Phosphatase = 110 U/L ALT = 98 U/LAAA10.01.2016Alkaline Phosphatase = 180Alkaline Phosphatase = 110 U/L ALT = 98 U/LAA10.01.2016Alkaline Brosphatase = 5.0 mg/dLTotal Bilirubin = 1.8 mg/dLTotal Bilirubin = 1.8 mg/dLCotal Bilirubin = 5.0 mg/dLCaaaRelevant medical/medication history e.g. allergies, race, pregnancy, smoking, alcohol use, hepatic/reater.)aaSeriousness of the reaction: NoIf yes(Please tick anyone)aDeath (dd/mm/yyyy)baaaLife threatening Hospitalisation (initial or prolonged)aaaDisability Congenital anomaly Required intervention to prevent permanent impairment/damageaa</td>	Name Brand/G eneric)Dose usedRoute UsedFrequenc y (OD, BD, etc.)Therapy dates DateTab. Diclofena c50 mgOralBD09.01.20112.01.201Tab. c50 mgOralBD09.01.20112.01.201Caab666Caab10.01.20166Caaba10.01.20166Caaba10.01.20166Caaba10.01.201610.01.2016Alkaline Phosphatase = 180Alkaline Phosphatase = 110 U/L ALT = 98 U/LAAA10.01.2016Alkaline Phosphatase = 180Alkaline Phosphatase = 110 U/L ALT = 98 U/LAA10.01.2016Alkaline Brosphatase = 5.0 mg/dLTotal Bilirubin = 1.8 mg/dLTotal Bilirubin = 1.8 mg/dLCotal Bilirubin = 5.0 mg/dLCaaaRelevant medical/medication history e.g. allergies, race, pregnancy, smoking, alcohol use, hepatic/reater.)aaSeriousness of the reaction: NoIf yes(Please tick anyone)aDeath (dd/mm/yyyy)baaaLife threatening Hospitalisation (initial or prolonged)aaaDisability Congenital anomaly Required intervention to prevent permanent impairment/damageaa

Categories	Time Sequence	Other Drug Disease Ruled Out	Dechallenge	Rechallenge
Certain	Yes	Yes	Yes	Yes
Probable	Yes	Yes	Yes	No
Possible	Yes	No	No	No
Unlikely	No	No	No	No

## **Result** :

IPC's ADR reporting form was filled and causality assessments using various scales was performed.

# FDSPharmacy Learn and Educate



Hello	
Friends	
lf you Get A	ny Help From This Notes /
Videos	
Next You Tu	rn To Help Us
Please Cont	ribute Some Amount
To Our	
FDSPharmac	y Team
Phone Pe	6398439940
Paytm	6398439940
Google Pay	6398439940

Amir Khan



